RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
Publication
, Journal Article
Diwakar, D; Choi, T; Tawbi, TH; Kirkwood, JM
Published in: Annals of Oncology
August 2014
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
August 2014
Volume
25
Issue
8
Start / End Page
1670 / 1671
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Diwakar, D., Choi, T., Tawbi, T. H., & Kirkwood, J. M. (2014). RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25(8), 1670–1671. https://doi.org/10.1093/annonc/mdu196
Diwakar, D., T. Choi, T. H. Tawbi, and J. M. Kirkwood. “RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.” Annals of Oncology 25, no. 8 (August 2014): 1670–71. https://doi.org/10.1093/annonc/mdu196.
Diwakar D, Choi T, Tawbi TH, Kirkwood JM. RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology. 2014 Aug;25(8):1670–1.
Diwakar, D., et al. “RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.” Annals of Oncology, vol. 25, no. 8, Elsevier BV, Aug. 2014, pp. 1670–71. Crossref, doi:10.1093/annonc/mdu196.
Diwakar D, Choi T, Tawbi TH, Kirkwood JM. RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology. Elsevier BV; 2014 Aug;25(8):1670–1671.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
August 2014
Volume
25
Issue
8
Start / End Page
1670 / 1671
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis